scholarly journals Pancreatitis and Biliary Obstruction Secondary to Duodenal Metastasis from Rapidly Progressing Lung Adenocarcinoma Treated with Common Bile Duct Stenting

2020 ◽  
Vol 13 (2) ◽  
pp. 962-967
Author(s):  
Robert Sean O’Neill ◽  
Tuan Duong ◽  
Welan Dionela ◽  
Claudia Rogge ◽  
Daniel Brungs
Keyword(s):  
Lung Adenocarcinoma ◽  
Single Agent ◽  
Rapid Progression ◽  
Disease Response ◽  
Endoscopic Intervention ◽  
Small Bowel Metastasis ◽  
Duodenal Metastasis ◽  
Lung Adenocarcinoma Patient ◽  
Bile Duct Stenting ◽  
Fdg Pet Ct

Non-small cell lung cancer (NSCLC) is characterised by diffuse metastases, with common sites being the brain, liver, bones, and adrenal glands. Small bowel metastasis from NSCLC is a rare phenomenon, particularly in patients with an adenocarcinoma histology. We report the case of a 56-year-old lung adenocarcinoma patient with a duodenal metastasis diagnosed on FDG/PET-CT and confirmed on duodenal biopsy. Although initially asymptomatic, he subsequently presented with obstructive jaundice secondary to rapid local disease progression at the duodenal metastasis, requiring endoscopic intervention for biliary drainage. He was commenced on single agent pembrolizumab, with disease response on subsequent follow-up. This case highlights a rare case of gastrointestinal metastasis from NSCLC requiring endoscopic intervention due to rapid progression of the disease at the site of metastasis.

scholarly journals Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma

2021 ◽  
Vol 9 (2) ◽  
pp. e001967 ◽  
Author(s):  
Dongsheng Yue ◽  
Juanjuan Qian ◽  
Zhipeng Chen ◽  
Bin Zhang ◽  
Peng Chen ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Kinase Inhibitors ◽  
Lymphocyte Activation ◽  
Inflammatory Factors ◽  
Second Line ◽  
Disease Response ◽  
Lung Adenocarcinoma Patient ◽  
Third Line ◽  
Line Setting

Patients with ROS1-rearranged non-small cell lung cancer (NSCLC) inevitably relapse after first-line targeted therapy with tyrosine kinase inhibitors. Efficacy of checkpoint inhibitor-based therapy on ROS1-positive NSCLC in second-line setting and change of immune factors during treatment are rarely studied. We report a ROS1-rearranged stage ⅢB lung adenocarcinoma patient who was resistant to ceritinib after developing a secondary ROS1 F2004L mutation. He received eight cycles of nivolumab plus chemotherapy and had an initial partial response, but brain metastases appeared in the seventh cycle. Lorlatinib was confirmed to have activity against CD74–ROS1 with F2004L in vitro, and was administered to this patient as the third-line therapy. The patient responded well to lorlatinib and had no relapse. We explored the tumor immune microenvironment (TIME) during immune-chemotherapy by multiplex immunohistochemistry, RNA sequencing, and multiplex plasma protein immunoassay. The results show that the TIME was active and plasma inflammatory factors were increased when the patient responded to immune-chemotherapy, while the plasma inhibitory checkpoint proteins, lymphocyte-activation gene 3, B and T lymphocyte attenuator, programmed cell death ligand 1 (PD-L1), and PD-1, were increased when the disease progressed. Moreover, the PD-L1 expression on tumor tissue was upregulated during treatment, predicting the limited benefit from immune-chemotherapy. This case report suggests that lorlatinib is a better choice than immune-chemotherapy in second-line setting for patients with similar genomic characteristics, and that monitoring the immune components during immunotherapy may help to predict disease response.

scholarly journals Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

2021 ◽  
Vol 14 (10) ◽  
pp. 101179
Author(s):  
Joshua C. Rosen ◽  
Jessica Weiss ◽  
Nhu-An Pham ◽  
Quan Li ◽  
Sebastiao N. Martins-Filho ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Antitumor Efficacy ◽  
Lung Adenocarcinoma Patient

BRAF-MAD1L1 and BRAF-ZC3H7A: novel gene fusion in Rhabdomyosarcoma and Lung adenocarcinoma

2021 ◽  
Author(s):  
Jiang Da ◽  
Hui Jin ◽  
Xinliang Zhou ◽  
Shaoshuang Fan ◽  
Mian Xu ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Gene Fusion ◽  
Tumor Resection ◽  
Kinase Domain ◽  
Rapid Progression ◽  
First Line ◽  
Case Presentation ◽  
First Case ◽  
Exon 11 ◽  
Domain Exon

Abstract Background: Rhabdomyosarcoma (RMS) and lung adenocarcinoma (LADC) epitomizes the success of cancer prevention by the development of conventional therapy, but huge challenges remain in the therapy of advanced diseases.Case presentation: We reported two cases of novel BRAF gene fusion. The first case was a 34-year-old female with RMS harboring a BRAF-MAD1L1 fusion. She suffered tumor resection, recurrence and rapid progression. The second case was a 72-year-old female with LADC harboring a BRAF-ZC3H7A fusion, and she gained rapid progression after receiving a first-line course of chemotherapy.Conclusions: These two BRAF fusions retain the intact BRAF kinase domain (exon 11-18) and showed poor prognosis in RMS and LADC.

Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT

Lung Cancer ◽  
2013 ◽  
Vol 79 (3) ◽  
pp. 242-247 ◽  
Author(s):  
Hongyoon Choi ◽  
Jin Chul Paeng ◽  
Dong-Wan Kim ◽  
June Koo Lee ◽  
Chang Min Park ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Fdg Pet ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals A new KIF5B-ERBB4 gene fusion in a lung adenocarcinoma patient

2021 ◽  
pp. 00582-2020
Author(s):  
Edouard Guenzi ◽  
Johan Pluvy ◽  
Alice Guyard ◽  
Marina Nguenang ◽  
Khedidja Rebah ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Gene Fusion ◽  
Lung Adenocarcinoma Patient ◽  
Erbb4 Gene

scholarly journals Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Xiaomin Niu ◽  
Yingjia Sun ◽  
David Planchard ◽  
Luting Chiu ◽  
Jian Bai ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Nsclc Patient ◽  
Braf Inhibitor ◽  
Progression Free Survival ◽  
Braf V600e ◽  
First Line ◽  
Liquid Biopsies ◽  
Durable Response ◽  
Platinum Based Chemotherapy ◽  
Lung Adenocarcinoma Patient

BackgroundImmune checkpoint inhibitor (ICPi) has become a major treatment in advanced non-small cell lung cancer (NSCLC) and demonstrated a clinical benefit for NSCLC patients with high programmed death ligand-1 (PD-L1) expression without EGFR/ALK/ROS1 drivers; however, the benefit in BRAF V600E NSCLC is so far unknown. Here, we report a case of prolonged tumor response to the combination of immunotherapy with chemotherapy in a non-smoking BRAF V600E NSCLC patient.Materials and MethodsWe verify a co-expression of BRAF V600E mutation and PD-L1 high expression more than 50% on formalin-fixed paraffin-embedded tumor sample of a newly diagnosed lung adenocarcinoma patient by immunohistochemistry and BRAF V600E/EGFR/ALK/ROS1 Mutations Detection Kit. The tissue and liquid biopsies were further subjected to next-generation sequencing (NGS) for identification of mutations with progression on immunotherapy and BRAF inhibitor (BRAFi). The patient had provided written informed consent and authorized the publication of clinical case.ResultsWe demonstrate the case of 62-year-old female non-smoker with high PD-L1 expression and BRAF V600E mutated NSCLC. The progression-free survival (PFS) of first-line combination of atezolizumab with platinum-based chemotherapy and sequential second-line treatment with BRAFi Vemurafenib are 20 and 5.5 months, respectively.ConclusionThis case shows a durable response to ICPi in BRAF V600E non-smoking lung adenocarcinoma with PFS of 20 months under first-line atezolizumab plus chemotherapy treatment. The case supports the idea that the combination immunotherapy may be an attractive option for BRAF V600E mutated non-smoking NSCLC with high PD-L1 expression.

Sign in / Sign up

Export Citation Format

Share Document